MSCL: Phase II trials of forazapadin show early promise in muscle regeneration, with pivotal data expected soon
The conference highlighted forazapadin's novel approach to muscle regeneration in Duchenne and FSHD, with two phase II trials set to deliver key data by early next year. Early results show functional and biomarker improvements, and expansion into FSHD is planned.Based on Satellos Bioscience Inc [MS…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.